• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Autologous Cell Therapy Effective in Wound Treatment

Article

Researchers applied EB-101, a new cell therapy, to patients with recessive dystrophic epidermolysis bullosa with positive results.

Investigators assessed the efficacy of EB-101, an investigational autologous cell therapy, on patients with recessive dystrophic epidermolysis bullosa (RDEB) and found that the majority of wounds (81%) treated with EB-101 showed healing of ≥50% and a reduction in pain severity, meeting the co-primary endpoints.1 The findings were reported in a poster presented at the 2023 Society for Pediatric Dermatology Meeting, July 13-16, 2023, in Asheville, North Carolina.

tibanna79/AdobeStock

tibanna79/AdobeStock

RDEB patients “have mutations in COL7A1, the gene encoding Type VII collagen.”1 By taking 2 punch biopsies from a patient with RDEB, 6 grafts measuring 40 cm2 are produced in 25 days using a “retrovirus expressing the corrected COL7A1 gene.”1 In a phase 3, randomized, intrapatient-controlled trial (VIITAL), 11 RDEB patients with large, chronic, locational matched wound pairs received EB-101 treatment or standard of care (controls). 

Eligible participants had to be at least 6 years old, have 2 or more matched, large chronic wounds, and have no evidence or history of squamous cell carcinoma in the area that would be treated with EB-101. Co-primary endpoints were ≥50% wound healing at week 24, and a reduction in pain at week 24. A secondary endpoint was complete wound healing of the wound at weeks 12 and 24.

EB-101 was applied to 43 wounds across 11 patients, and control treatment was used across 43 matched wounds. At week 24, 81% of wounds treated with EB-101 achieved ≥50% healing compared to 16% of control wounds (P < .001). Severity of pain from baseline to week 24 was reduced by 3.07 for EB-101—treated wounds compared to 0.90 for control wounds (P < .001).

EB-101 was also effective in ≥75% and 100% wound healing, meeting secondary endpoints. Additional exploratory endpoints that were met included a reduction in itch and wound blistering. A decrease in pain at earlier weeks (6 or 12) was also achieved.

Based on their study, researchers concluded that, “EB-101 application demonstrated a favorable risk-benefit profile in both adult and pediatric patients with RDEB.”

Reference

  1. Mittal V, Tang J, Marinkovich M, et al. Phase 3 randomized, intrapatient-controlled trial of an investigational collagen type VII gene-corrected autologous cell therapy, EB-101, for the treatment of RDEB. Poster presented at the 2023 Society for Pediatric Dermatology Meeting; July 13-16, 2023. Asheville, NC.
Related Videos
© 2024 MJH Life Sciences

All rights reserved.